Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923Phase 1Active, not recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risvutatug rezetecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 24 months. Started Jan 2026; status: active, not recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07462923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462923.